Danielle Antalffy, an analyst from UBS, has initiated a new Buy rating on PROCEPT BioRobotics (PRCT).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Danielle Antalffy has given her Buy rating due to a combination of factors that suggest a promising growth trajectory for PROCEPT BioRobotics. The company’s focus on increasing utilization of its existing installed base and potential for greenfield system placements are expected to drive significant growth. The market has not fully appreciated these factors, which, combined with margin expansion and operational efficiency improvements, present a compelling investment opportunity.
Furthermore, the company’s revenue growth projections are ahead of consensus estimates, with anticipated improvements in gross margins and a clear path to profitability by 2027. The current stock price reflects a deep discount, and upcoming catalysts, such as the Investor Day and resolution of temporary destocking issues, are likely to lead to a re-rating of the stock. This positions PROCEPT BioRobotics favorably against its high-growth peers in the MedTech sector.
In another report released on December 8, Piper Sandler also reiterated a Buy rating on the stock with a $50.00 price target.
PRCT’s price has also changed dramatically for the past six months – from $62.120 to $36.030, which is a -42.00% drop .